Asset recovery partners help the NHS unlock value through responsible linac deinstallation

As NHS cancer centres invest in the latest generation of radiotherapy technology, an important opportunity is emerging through linac replacement programmes. According to diagnostic imaging equipment marketplace Quest Meditech, value can be recovered from legacy equipment while supporting global access to cancer care.

Procurement, installation, commissioning and clinical implementation of a linac require careful planning and significant investment, the company says. Many linacs reaching the end of their service in the NHS retain operational value and can deliver treatments in healthcare systems around the world.

This is where specialist deinstallation and asset recovery partners can play a role, the company says. It is helping trusts maximise the value of retiring radiotherapy equipment through safe, compliant and professionally managed deinstallation services. “By combining engineering expertise with international market knowledge, Quest Meditech enables hospitals to transform redundant assets into a financial and environmental benefit. Revenue generated through the resale of suitable equipment can help offset replacement costs, while responsible refurbishment and redeployment support NHS sustainability objectives by extending the life span of specialised medical technology,” it explains. Rather than becoming waste, many systems are given a second life in regions where access to advanced cancer treatment remains limited.

“Equally important is ensuring deinstallation is completed safely and efficiently, minimising disruption to clinical services and maintaining full regulatory compliance throughout the process,” the company concludes.

Read this report on page 5 of the October 2026 issue of RAD Magazine.